# æ–‡ç»ç¸½è¦½ç´¢å¼•

**æœ€å¾Œæ›´æ–°**ï¼š2026-01-10
**ç”¨é€”**ï¼šçµ±æ•´æ‰€æœ‰å·²è®€è«–æ–‡çš„ç‹€æ…‹èˆ‡åˆ†é¡

---

## ğŸ“Š é–±è®€ç‹€æ…‹ç¸½è¦½

| ç‹€æ…‹ | æ•¸é‡ | èªªæ˜ |
|------|------|------|
| âœ… å·²å®Œæ•´åˆ†æï¼ˆæœ‰æ·±åº¦è§£æï¼‹ç°¡å ±ï¼‰ | 5 | Meeting 15-18 è«–æ–‡ |
| ğŸ“‹ å·²é–±è®€æ‘˜è¦èˆ‡æ–¹æ³• | 2 | SMOTE+SHAP 2025, Prediabetes 2024 |
| ğŸ“Œ å¾…æ·±å…¥åˆ†æ | 1 | Hung et al. 2021 |
| ğŸ“‹ åŸºæœ¬è³‡è¨Šå·²æ•´ç† | å¤šç¯‡ | è¦‹ç³»çµ±æ€§æ–‡ç»å›é¡§ |

### æŒ‰ Meeting é€²åº¦

| Meeting | è«–æ–‡ | ç‹€æ…‹ |
|---------|------|------|
| 15 | Liu et al. 2024 (å°ä¸­æ¦®ç¸½ç³–å°¿ç—…é æ¸¬) | âœ… å·²ç°¡å ± |
| 16 | Taiwan MTL 2025 (å¤šä»»å‹™å­¸ç¿’) | âœ… å·²ç°¡å ± |
| 17 | Dual Framework 2025 (Î´-FPG) | âœ… å·²ç°¡å ± |
| 18 | Taiwan MJ Hypertension 2024 (#5) | âœ… å·²ç°¡å ± |
| 19 | SMOTE+SHAP 2025 (#9) | ğŸ“‹ å·²é–±è®€ï¼ˆè©•ä¼°ç‚ºåƒè€ƒåƒ¹å€¼æœ‰é™ï¼‰|
| 19 | Prediabetes TaiwanMJ 2024 (#1) | ğŸ“‹ å·²é–±è®€æ‘˜è¦ |
| 19 | China Prediabetesâ†’Diabetes 2025 (#2) | ğŸ“‹ å·²é–±è®€ï¼ˆå‚™é¸è«–æ–‡ï¼‰ |
| 19 | **Kanegae Hypertension 2020** | âœ… **é¸å®šç‚º Meeting 19 è«–æ–‡** |

---

## ğŸ¯ æŒ‰ç–¾ç—…åˆ†é¡

### é«˜è¡€å£“ï¼ˆHypertensionï¼‰

#### âœ… Kanegae et al. (2020) - ä½¿ç”¨ AI çš„é«˜ç²¾åº¦é«˜è¡€å£“é æ¸¬ â­â­â­â­â­ã€Meeting 19 é¸å®šã€‘

- **æ¨™é¡Œ**ï¼šHighly precise risk prediction model for new-onset hypertension using artificial intelligence techniques
- **æœŸåˆŠ**ï¼šThe Journal of Clinical Hypertension
- **DOI**ï¼š[10.1111/jch.13759](https://doi.org/10.1111/jch.13759)
- **PMC**ï¼š[PMC8029685](https://pmc.ncbi.nlm.nih.gov/articles/PMC8029685/)
- **è³‡æ–™**ï¼šæ—¥æœ¬è·å ´å¥åº·æª¢æŸ¥ï¼Œ18,258 äººï¼Œ2005-2016
- **æ–¹æ³•**ï¼šXGBoost, Ensemble, Logistic Regression
- **æœ€ä½³æ¨¡å‹**ï¼šEnsemble (AUC 0.881)
- **æ ¸å¿ƒå‰µæ–°**ï¼š
  - **ç¸±å‘è®ŠåŒ–é‡ç‰¹å¾µ**ï¼šYear(-2) â†’ Year(-1) â†’ Year(0)
  - **Î” ç‰¹å¾µ**ï¼šChanges from Year(-2) to Year(-1) â† èˆ‡æˆ‘å€‘çš„ Delta1 ç›¸åŒï¼
- **ç‹€æ…‹**ï¼šâœ… **é¸å®šç‚º Meeting 19 è«–æ–‡**
- **èˆ‡æœ¬ç ”ç©¶é—œè¯åº¦**ï¼šâ­â­â­â­â­ (æœ€é«˜)
  - æ™‚é–“æ¶æ§‹å¹¾ä¹ç›¸åŒï¼ˆYear(-2), Year(-1), Year(0) vs T1, T2, T3ï¼‰
  - åŒæ¨£ä½¿ç”¨ç¸±å‘è®ŠåŒ–é‡ç‰¹å¾µ
  - è­‰æ˜ Î” ç‰¹å¾µåœ¨é«˜è¡€å£“é æ¸¬ä¸Šæœ‰æ•ˆ
- **ç›¸é—œæ–‡æª”**ï¼š
  - [Paper_Kanegae_Hypertension_2020.md](summaries/Paper_Kanegae_Hypertension_2020.md)
  - [Kanegae_Hypertension_2020_ä¸­æ–‡ç¿»è­¯.md](translations/Kanegae_Hypertension_2020_ä¸­æ–‡ç¿»è­¯.md)

#### âœ… Taiwan MJ Hypertension (2024) - ä¸‹æ¬¡å¥æª¢é«˜è¡€å£“é æ¸¬ â­â­â­â­â­ã€Meeting 18ã€‘
- **æ¨™é¡Œ**ï¼šNext-visit prediction and prevention of hypertension using large-scale routine health checkup data
- **æœŸåˆŠ**ï¼šPLoS ONE
- **DOI**ï¼š[10.1371/journal.pone.0312370](https://doi.org/10.1371/journal.pone.0312370)
- **PMC**ï¼š[PMC11560048](https://pmc.ncbi.nlm.nih.gov/articles/PMC11560048/)
- **è³‡æ–™**ï¼šTaiwan MJ Cohortï¼ˆç¾å…†å¥æª¢è³‡æ–™ï¼‰ï¼Œå¤§è¦æ¨¡å¥æª¢è³‡æ–™
- **æ–¹æ³•**ï¼šRF, XGBoost, LightGBM ç­‰
- **æ ¸å¿ƒç™¼ç¾**ï¼š
  - **è¨ªå•æ¬¡æ•¸è¶Šå¤šï¼Œé æ¸¬è¶Šæº–**ï¼ˆ4+ æ¬¡æœ€ä½³ï¼‰
  - å¤šæ™‚é–“é»ç‰¹å¾µä¸²æ¥ï¼ˆT1 + T2 + ... + TNï¼‰
  - èˆ‡æœ¬ç ”ç©¶çš„ç¸±å‘è¨­è¨ˆæ¦‚å¿µä¸€è‡´
- **ç‹€æ…‹**ï¼šâœ… å·²ç°¡å ±å®Œæˆï¼ˆMeeting 18ï¼‰
- **ç›¸é—œæ–‡æª”**ï¼š
  - [Meeting_18_Notes.md](../meeting_notes/Meeting_18_Notes.md)
  - [è«–æ–‡å€™é¸æ¸…å–® #5](../memos/è«–æ–‡å€™é¸æ¸…å–®_å¾Dual2025å»¶ä¼¸.md)

#### ğŸ“Œ Hung et al. (2021) - éš±åŒ¿æ€§é«˜è¡€å£“é æ¸¬
- **æœŸåˆŠ**ï¼šFrontiers in Cardiovascular Medicine, 8:778306
- **DOI**ï¼š[10.3389/fcvm.2021.778306](https://doi.org/10.3389/fcvm.2021.778306)
- **PDFä½ç½®**ï¼š[fcvm-08-778306.pdf](../references/fcvm-08-778306.pdf)
- **è³‡æ–™**ï¼šå°ç£å…­å®¶é†«å­¸ä¸­å¿ƒ + å°åŒ—æ¦®ç¸½ï¼Œ970+416äºº
- **æ–¹æ³•**ï¼šLR, RF, XGBoost, ANN + SMOTE-NC
- **æœ€ä½³æ¨¡å‹**ï¼šRF (AUC 0.851/0.837)
- **é—œéµç‰¹å¾µ**ï¼šDBP, MAP, SBP, PP, beta-blocker, HDL-C
- **ç‹€æ…‹**ï¼šğŸ“Œ æœ‰PDFï¼Œå¾…æ·±å…¥åˆ†æ
- **ç›¸é—œæ–‡æª”**ï¼š[Q2_Taiwan_Literature_Review.md](../research_plans/Q2_Taiwan_Literature_Review.md)

#### ğŸ“‹ Lin et al. (2024) - è¡€æ¸…å°¿é…¸èˆ‡é«˜è¡€å£“é—œä¿‚
- **æœŸåˆŠ**ï¼šFrontiers in Endocrinology
- **DOI**ï¼š10.3389/fendo.2024.1343998
- **æ¨™é¡Œ**ï¼šPoor serum uric acid control increases the risk of hypertension
- **è³‡æ–™**ï¼šä¸­åœ‹ï¼Œ6,052äººï¼Œè¿½è¹¤6å¹´
- **ç™¼ç¾**ï¼šå°¿é…¸æ°´å¹³è®ŠåŒ–èˆ‡é«˜è¡€å£“é¢¨éšªå‘ˆç·šæ€§ç›¸é—œ
- **ç‹€æ…‹**ï¼šğŸ“‹ åŸºæœ¬è³‡è¨Šå·²æ•´ç†
- **é–±è®€æ—¥æœŸ**ï¼š2025-09-09

---

### ç³–å°¿ç—…ï¼ˆDiabetesï¼‰

#### âœ… Liu et al. (2024) - å°ç£ç¬¬äºŒå‹ç³–å°¿ç—…ç™¼ç—…é æ¸¬
- **æœŸåˆŠ**ï¼šDiagnostics, 15(1), 72
- **DOI**ï¼š[10.3390/diagnostics15010072](https://doi.org/10.3390/diagnostics15010072)
- **PDFä½ç½®**ï¼š[diagnostics-15-00072.pdf](../references/diagnostics-15-00072.pdf)
- **è³‡æ–™**ï¼šå°ä¸­æ¦®ç¸½EHRï¼Œ6,687äººï¼Œè¿½è¹¤10å¹´
- **æ–¹æ³•**ï¼šLR, RF, XGBoost
- **æœ€ä½³æ¨¡å‹**ï¼šXGBoost (AUC 0.93)
- **é—œéµç‰¹å¾µ**ï¼šHbA1c, FBG, Weight, fT4, TG
- **ç‹€æ…‹**ï¼šâœ… å·²å®Œæ•´åˆ†æ
- **ç›¸é—œæ–‡æª”**ï¼š
  - [Liu_2024_TCVGH_Diabetes_Prediction_æ·±åº¦è§£æ.md](Liu_2024_TCVGH_Diabetes_Prediction_æ·±åº¦è§£æ.md)
  - ç°¡å ±æª”ï¼šmeeting15_21138X006_ç´€ä¼¯å–¬_wVBA.pptm (å·²å ±å‘Šå®Œæˆ)

#### âœ… Dual Framework (2025) - å°ç£é’å¹´ç”·æ€§å‰é©…ç³–å°¿ç—…é æ¸¬ â­â­â­â­â­ã€Meeting 17ã€‘
- **æœŸåˆŠ**ï¼šDiagnostics, 15(19), 2507
- **DOI**ï¼š[10.3390/diagnostics15192507](https://doi.org/10.3390/diagnostics15192507)
- **PDFä½ç½®**ï¼š[diagnostics-15-02507.pdf](../references/diagnostics-15-02507.pdf) (3.5 MB)
- **è³‡æ–™**ï¼šå°ç£ MJ å¥åº·ç¯©æª¢ä¸­å¿ƒï¼Œ6,247äºº (18-35æ­²ç”·æ€§)ï¼Œè¿½è¹¤5.9å¹´
- **æ–¹æ³•**ï¼šé›™æ¡†æ¶ (é€£çºŒå€¼Î´-FPG + äºŒå…ƒåˆ†é¡) | RF, SGB, XGBoost, Elastic Net
- **å¯è§£é‡‹æ€§**ï¼šSHAP
- **é—œéµç™¼ç¾**ï¼šÎ´-FPG (è¡€ç³–è®ŠåŒ–é‡) é æ¸¬ï¼Œèˆ‡æœ¬ç ”ç©¶çš„ Î” ç‰¹å¾µæ¦‚å¿µç›¸åŒ
- **ç‹€æ…‹**ï¼šâœ… å·²ç°¡å ±å®Œæˆï¼ˆMeeting 17ï¼‰
- **èˆ‡æœ¬ç ”ç©¶é—œè¯åº¦**ï¼šâ­â­â­â­â­ (æœ€é«˜)
  - ç¸±å‘è®ŠåŒ–é‡ç‰¹å¾µï¼ˆÎ´-FPG = Î”ç‰¹å¾µï¼‰
  - é›™æ¡†æ¶è¨­è¨ˆï¼ˆé€£çºŒå€¼ + åˆ†é¡ï¼‰
  - SHAP å¯è§£é‡‹æ€§
  - å°ç£æœ¬åœŸè³‡æ–™
  - è¡€æ¶²æª¢é©—é …ç›®å®Œæ•´ï¼ˆå«å°¿é…¸ï¼‰
- **ç›¸é—œæ–‡æª”**ï¼š
  - [Meeting_17_Preparation_Plan.md](../meeting_notes/Meeting_17_Preparation_Plan.md)
  - [Dual_2025_æ·±åº¦è§£æ.md](Dual_2025_æ·±åº¦è§£æ.md)
  - [Meeting_15-17_Papers_Summary.md](Meeting_15-17_Papers_Summary.md)

#### ğŸ“‹ Prediabetes TaiwanMJ (2024) - Dual 2025 å‰ä½œã€Meeting 19 å€™é¸ã€‘
- **æ¨™é¡Œ**ï¼šMachine Learning Prediction of Prediabetes in a Young Male Chinese Cohort with 5.8-Year Follow-Up
- **æœŸåˆŠ**ï¼šDiagnostics (MDPI)
- **DOI**ï¼š[10.3390/diagnostics14100979](https://doi.org/10.3390/diagnostics14100979)
- **PMC**ï¼š[PMC11119884](https://pmc.ncbi.nlm.nih.gov/articles/PMC11119884/)
- **è³‡æ–™**ï¼šTaiwan MJ Cohortï¼Œ6,247 ç”·æ€§ï¼Œ5.8 å¹´è¿½è¹¤
- **æ–¹æ³•**ï¼šRF, SGB, XGBoost, Elastic Netï¼ˆç„¡ SMOTEï¼‰
- **é—œéµç‰¹å¾µ**ï¼šFPGbase (100%), Body Fat (28%), Creatinine, TSH, WBC
- **ç‹€æ…‹**ï¼šğŸ“‹ å·²é–±è®€æ‘˜è¦èˆ‡æ–¹æ³•
- **èˆ‡ Dual 2025 é—œä¿‚**ï¼šåŒä¸€ç ”ç©¶åœ˜éšŠçš„å‰ä½œï¼Œå–®ä»»å‹™ â†’ é›™ä»»å‹™æ¼”é€²
- **ç›¸é—œæ–‡æª”**ï¼š[Paper_Prediabetes_TaiwanMJ_2024.md](../memos/Paper_Prediabetes_TaiwanMJ_2024.md)

#### ğŸ“‹ SMOTE+SHAP Framework (2025) - å¯è§£é‡‹æ€§æ¡†æ¶ã€Meeting 19 å€™é¸ã€‘
- **æ¨™é¡Œ**ï¼šInterpretable Machine Learning Framework for Diabetes Prediction: Integrating SMOTE Balancing with SHAP Explainability
- **æœŸåˆŠ**ï¼šHealthcare (MDPI)
- **DOI**ï¼š[10.3390/healthcare13202588](https://doi.org/10.3390/healthcare13202588)
- **PMC**ï¼š[PMC12563896](https://pmc.ncbi.nlm.nih.gov/articles/PMC12563896/)
- **è³‡æ–™**ï¼šKaggle å…¬é–‹è³‡æ–™é›†ï¼Œ100,000 ç­†ï¼ˆæ©«æ–·é¢ï¼‰
- **æ–¹æ³•**ï¼šRF, GB, SVM, LR, XGBoost + SMOTE (k=5) + SHAP
- **æœ€ä½³çµæœ**ï¼šRF (AUC 0.998)ï¼ŒRecall 99.5%
- **ç‹€æ…‹**ï¼šğŸ“‹ å·²é–±è®€å…¨æ–‡
- **è©•ä¼°**ï¼šâš ï¸ **åƒè€ƒåƒ¹å€¼æœ‰é™**
  - æ©«æ–·é¢è¨­è¨ˆï¼ˆéç¸±å‘è¿½è¹¤ï¼‰
  - ç”¨ glucose é æ¸¬ diabetesï¼ˆè¿‘ä¹ tautologicalï¼‰
  - AUC 0.998 éé«˜ï¼Œå¯èƒ½è³‡æ–™ç‰¹æ€§é€ æˆ
  - ä¸»è¦è²¢ç»ç‚ºæ•´åˆæ¡†æ¶ï¼ŒæŠ€è¡“å‰µæ–°æœ‰é™
- **å¯å€Ÿé¡ä¹‹è™•**ï¼š
  - SMOTE åœ¨ CV fold å…§åŸ·è¡Œï¼ˆé˜²æ­¢ data leakageï¼‰
  - SHAP interaction analysis
  - å¤šæŒ‡æ¨™å ±å‘Šï¼ˆSensitivity, Specificity, NPVï¼‰
- **ç›¸é—œæ–‡æª”**ï¼š[Paper_SMOTE_SHAP_2025.md](../memos/Paper_SMOTE_SHAP_2025.md)

#### ğŸ“‹ China Prediabetesâ†’Diabetes (2025) - 5 å¹´ç¸±å‘é æ¸¬ã€Meeting 19 å‚™é¸ã€‘

- **æ¨™é¡Œ**ï¼šDevelopment of a 5-Year Risk Prediction Model for Transition From Prediabetes to Diabetes Using Machine Learning
- **æœŸåˆŠ**ï¼šJMIR (Journal of Medical Internet Research)
- **DOI**ï¼š[10.2196/73190](https://doi.org/10.2196/73190)
- **PDFä½ç½®**ï¼š[JMIR_Prediabetes_Diabetes_2025.pdf](../references/JMIR_Prediabetes_Diabetes_2025.pdf)
- **è³‡æ–™**ï¼š
  - ä¸»è¦éšŠåˆ—ï¼šå±±æ±ç¬¬ä¸€é†«ç§‘å¤§å­¸é™„å±¬é†«é™¢ï¼Œ6,270 äºº
  - å¤–éƒ¨é©—è­‰ï¼šæ¿±å·é†«å­¸é™¢é™„å±¬é†«é™¢ï¼Œ2,157 äºº
  - è¿½è¹¤æœŸï¼š5 å¹´ï¼Œ**æ¯å¹´ä¸€æ¬¡å¥æª¢**
  - é€²å±•ç‡ï¼š41.6%ï¼ˆä¸»è¦ï¼‰/ 35.2%ï¼ˆå¤–éƒ¨ï¼‰
- **æ–¹æ³•**ï¼š7 ç¨® ML æ¨¡å‹æ¯”è¼ƒï¼ˆLR, RF, SVM, MLP, XGBoost, LightGBM, **CatBoost**ï¼‰
- **æœ€ä½³æ¨¡å‹**ï¼š**CatBoost** (AUC 0.819 Test / 0.807 External)
- **ç‰¹å¾µé¸æ“‡**ï¼šRFE-Logisticï¼Œå¾ 42 å€‹é¸å‡º 14 å€‹ç‰¹å¾µ
- **SHAP Top 6**ï¼šFBG, HDL, ALT/AST, BMI, Age, MONO
- **ç‹€æ…‹**ï¼šğŸ“‹ å·²é–±è®€ï¼ˆå‚™é¸è«–æ–‡ï¼‰
- **èˆ‡æœ¬ç ”ç©¶é—œè¯åº¦**ï¼šâ­â­â­â­
  - è³‡æ–™è¦æ¨¡ç›¸è¿‘ï¼ˆ~6,000 + ~2,000 vs ~6,000 + ~1,000ï¼‰
  - ç¸±å‘å¤šæ¬¡å¥æª¢è¨­è¨ˆ
  - æœ‰å¤–éƒ¨é©—è­‰ï¼ˆæˆ‘å€‘ä¹Ÿæœ‰ CLSAï¼‰
  - **CatBoost æ˜¯æˆ‘å€‘æ²’è©¦éçš„æ¨¡å‹**
  - âš ï¸ **ä»–å€‘æ²’ç”¨ Î” ç‰¹å¾µ**ï¼ˆKanegae 2020 æœ‰ï¼Œæ›´é©åˆä½œç‚ºæ–¹æ³•è«–é©—è­‰ï¼‰
- **å¯å€Ÿé¡ä¹‹è™•**ï¼š
  - è€ƒæ…®åŠ å…¥ CatBoost æ¨¡å‹
  - Calibration curves + DCA è©•ä¼°
  - DeLong test çµ±è¨ˆæª¢å®š
- **ç›¸é—œæ–‡æª”**ï¼š
  - [Paper_China_Prediabetes_Diabetes_2025.md](summaries/Paper_China_Prediabetes_Diabetes_2025.md)
  - [JMIR_Prediabetes_Diabetes_2025_ä¸­æ–‡ç¿»è­¯.md](translations/JMIR_Prediabetes_Diabetes_2025_ä¸­æ–‡ç¿»è­¯.md)

---

### é«˜è¡€è„‚ï¼ˆDyslipidemiaï¼‰

âš ï¸ **å°ç£é«˜è¡€è„‚é æ¸¬ç ”ç©¶è¼ƒå°‘**ï¼Œä¸»è¦ç‚ºåœ‹éš›ç ”ç©¶ï¼ˆè¦‹ç³»çµ±æ€§æ–‡ç»å›é¡§ï¼‰

---

### ä»£è¬ç—‡å€™ç¾¤ï¼ˆMetabolic Syndromeï¼‰

#### ğŸ“‹ å°ç£æˆäººä»£è¬ç—‡å€™ç¾¤ç›¸é—œç ”ç©¶
- å¤šç¯‡å°ç£æœ¬åœŸç ”ç©¶ï¼ˆ2006-2020ï¼‰
- æ–¹æ³•ï¼šPCA, Decision Tree, ANN
- ç‹€æ…‹ï¼šåŸºæœ¬è³‡è¨Šå·²æ•´ç†
- ç›¸é—œæ–‡æª”ï¼š[Q2_Taiwan_Literature_Review.md](../research_plans/Q2_Taiwan_Literature_Review.md)

---

## ğŸ“‚ æŒ‰æ–‡ç”é¡å‹åˆ†é¡

### æ·±åº¦è§£ææ–‡æª”ï¼ˆå·²å®Œæˆï¼‰

1. [Liu_2024_TCVGH_Diabetes_Prediction_æ·±åº¦è§£æ.md](Liu_2024_TCVGH_Diabetes_Prediction_æ·±åº¦è§£æ.md)
   - ç ”ç©¶è¨­è¨ˆã€æ–¹æ³•ã€çµæœã€è¨è«–çš„å®Œæ•´åˆ†æ
   - èˆ‡æœ¬ç ”ç©¶çš„é—œè¯æ€§åˆ†æ
   - å•Ÿç¤ºèˆ‡å»ºè­°

### æ¼”è¬›ç¨¿æ–‡æª”ï¼ˆå·²å®Œæˆï¼‰

1. [Liu_2024_æ¼”è¬›ç¨¿_10é .md](Liu_2024_æ¼”è¬›ç¨¿_10é .md)
2. [Liu_2024_æ¼”è¬›ç¨¿_10é _ç²¾ç°¡ç‰ˆ.md](Liu_2024_æ¼”è¬›ç¨¿_10é _ç²¾ç°¡ç‰ˆ.md)

### ç¶œåˆæ–‡ç»å›é¡§æ–‡æª”

1. [Q2_Taiwan_Literature_Review.md](../research_plans/Q2_Taiwan_Literature_Review.md)
   - å°ç£ä¸‰é«˜é æ¸¬ç›¸é—œæ–‡ç»çš„ç³»çµ±æ€§æ•´ç†
   - æŒ‰ç–¾ç—…åˆ†é¡çš„è©³ç´°åˆ†æ
   - ç ”ç©¶ç¼ºå£èˆ‡æœ¬ç ”ç©¶çš„è²¢ç»

2. [Systematic_Literature_Review.md](Systematic_Literature_Review.md)
   - ç³»çµ±æ€§æ–‡ç»å›é¡§è¡¨æ ¼ï¼ˆ15ç¯‡åœ‹éš›ç ”ç©¶ï¼‰
   - æŒ‰ç ”ç©¶æ¨™çš„ã€æ–¹æ³•ã€è³‡æ–™é›†åˆ†é¡

3. [literature_review_memo.md](literature_review_memo.md)
   - æ—©æœŸæ–‡ç»é–±è®€ç­†è¨˜ï¼ˆ2025-09-09ï¼‰

### å…¶ä»–åƒè€ƒæ–‡æª”

1. [confusion_matrix_metrics.md](confusion_matrix_metrics.md)
   - è©•ä¼°æŒ‡æ¨™èªªæ˜

---

## ğŸ“‹ å¾…è®€è«–æ–‡æ¸…å–®

| å„ªå…ˆåº¦ | è«–æ–‡ | åŸå›  |
|--------|------|------|
| ğŸ”¥ | Dual 2025 å‰ä½œ (Prediabetes TaiwanMJ 2024) | äº†è§£æ¼”é€²è„ˆçµ¡ |
| ğŸ”¥ | SMOTE + SHAP Framework 2025 | æ–¹æ³•è«–åƒè€ƒ |

---

## ğŸ¯ Meeting 19 æº–å‚™é‡é»

### å·²å®Œæˆçš„ Meeting

| Meeting | è«–æ–‡ä¸»é¡Œ | ç‹€æ…‹ |
|---------|----------|------|
| 15 | Liu 2024 - å°ä¸­æ¦®ç¸½ç³–å°¿ç—… 10 å¹´é æ¸¬ | âœ… å·²ç°¡å ± |
| 16 | Taiwan MTL 2025 - å¤šä»»å‹™å­¸ç¿’æ…¢æ€§ç—…é æ¸¬ | âœ… å·²ç°¡å ± |
| 17 | Dual Framework 2025 - Î´-FPG é›™æ¡†æ¶ | âœ… å·²ç°¡å ± |
| 18 | Taiwan MJ Hypertension 2024 - å¤šæ¬¡å¥æª¢é æ¸¬ | âœ… å·²ç°¡å ± |

### Meeting 19 å¾…å®Œæˆä»»å‹™

1. **è«–æ–‡é¸è®€** âœ…
   - [x] é–±è®€ SMOTE+SHAP 2025ï¼ˆå·²è©•ä¼°ç‚ºåƒè€ƒåƒ¹å€¼æœ‰é™ï¼‰
   - [x] é–±è®€ Prediabetes TaiwanMJ 2024 æ‘˜è¦
   - [x] é–±è®€ China Prediabetesâ†’Diabetes 2025ï¼ˆå‚™é¸ï¼Œæœªä½¿ç”¨ Î” ç‰¹å¾µï¼‰
   - [x] **é¸å®š Kanegae Hypertension 2020** â† ä½¿ç”¨ Î” ç‰¹å¾µï¼Œé©—è­‰æˆ‘å€‘çš„æ–¹æ³•è«–
   - [x] æ·±åº¦è§£æä¸¦å»ºç«‹ memo + ä¸­æ–‡ç¿»è­¯

2. **å¯¦é©—ä»»å‹™**ï¼ˆä¾†è‡ª Meeting 18 Action Itemsï¼‰
   - [ ] 5-fold CVï¼ˆæ‰€æœ‰æ¨¡å‹é‡æ–°è·‘äº¤å‰é©—è­‰ï¼‰
   - [ ] Decision Tree (DT) æ¨¡å‹å¯¦é©—
   - [ ] MTL vs STL å®Œæ•´æ¯”è¼ƒå¯¦é©—
   - [ ] PySR æ¨¹æ·±åº¦å¯¦é©—

3. **æ–‡ä»¶ä»»å‹™**
   - [ ] æ’°å¯« Problem Definitionï¼ˆå«æ•¸å­¸å…¬å¼ï¼‰
   - [ ] æ•´ç†å¯¦é©—/å‡èªªåˆ—è¡¨ï¼ˆVariationsï¼‰

---

## ğŸ“Œ ç ”ç©¶æ–¹æ³•è«–ç¸½çµ

### å¸¸ç”¨æ¨¡å‹ï¼ˆæŒ‰å°ç£æ–‡ç»å‡ºç¾é »ç‡ï¼‰

1. **Random Forest** - å¤šç¯‡ç ”ç©¶è¡¨ç¾å„ªç•°
2. **XGBoost** - ç³–å°¿ç—…é æ¸¬æœ€ä½³ (Liu 2024: AUC 0.93)
3. **Logistic Regression** - åŸºæº–æ¨¡å‹
4. **SVM, ANN** - ç‰¹å®šæƒ…å¢ƒæœ‰å„ªå‹¢

### å¸¸ç”¨è³‡æ–™è™•ç†æŠ€è¡“

1. **é¡åˆ¥ä¸å¹³è¡¡**ï¼šSMOTE, SMOTE-NC, Over/Under-sampling
2. **ç¼ºå¤±å€¼**ï¼šMean imputation, KNN
3. **æ¨™æº–åŒ–**ï¼šZ-score normalization
4. **ç‰¹å¾µé¸æ“‡**ï¼šLASSO, RF feature importance, SHAP

### è©•ä¼°æŒ‡æ¨™ï¼ˆæ¨è–¦ï¼‰

- **ä¸»è¦**ï¼šAUC-ROCï¼ˆè™•ç†ä¸å¹³è¡¡è³‡æ–™ï¼‰
- **æ¬¡è¦**ï¼šAccuracy, Precision, Recall, F1-Score
- **è‡¨åºŠ**ï¼šSensitivity, Specificity, NPV, PPV
- **ç©©å®šæ€§**ï¼šäº¤å‰é©—è­‰ã€å¤–éƒ¨é©—è­‰

---

## ğŸ” ç ”ç©¶ç¼ºå£åˆ†æ

### æœ¬ç ”ç©¶å¡«è£œçš„ç¼ºå£

1. âœ… **å¤šæ¨™ç±¤åŒæ™‚é æ¸¬**ï¼ˆä¸‰é«˜åŒæ™‚é æ¸¬ï¼‰
2. âœ… **ç¸±å‘æ™‚åºç‰¹å¾µ**ï¼ˆÎ” è®ŠåŒ–é‡ï¼‰
3. âœ… **å°ç£æœ¬åœŸä¸‰é«˜ç¶œåˆç ”ç©¶**
4. âœ… **å¤šè³‡æ–™é›†é©—è­‰**ï¼ˆä¸­åœ‹ + åŠ æ‹¿å¤§ï¼‰

### æ€§èƒ½åŸºæº–ï¼ˆBenchmarkï¼‰

| ç–¾ç—… | AUC ç¯„åœ | åƒè€ƒæ–‡ç» |
|------|---------|---------|
| é«˜è¡€å£“ | 0.75-0.85 | Hung 2021 |
| ç³–å°¿ç—… | 0.76-0.99 | Liu 2024, Dual 2025, Chen 2023 |
| ä»£è¬ç—‡å€™ç¾¤ | 0.90-0.93 | ANN MetS 2006-14 |

**æœ¬ç ”ç©¶ç›®æ¨™**ï¼šAUC > 0.75, F1 > 0.65, Recall > 0.65

---

## ğŸ“– å¿«é€ŸæŸ¥æ‰¾

### æŒ‰ PDF æª”æ¡ˆä½ç½®æŸ¥æ‰¾

- [diagnostics-15-00072.pdf](../references/diagnostics-15-00072.pdf) â†’ Liu 2024 (ç³–å°¿ç—…) âœ…
- [diagnostics-15-02507.pdf](../references/diagnostics-15-02507.pdf) â†’ Dual 2025 (å‰é©…ç³–å°¿ç—…) ğŸ“Œ
- [fcvm-08-778306.pdf](../references/fcvm-08-778306.pdf) â†’ Hung 2021 (é«˜è¡€å£“) âš ï¸

### æŒ‰é—œéµè©æŸ¥æ‰¾

- **ç¸±å‘ç ”ç©¶ / Longitudinal**: Liu 2024, Dual 2025
- **SHAP**: Dual 2025
- **å°ç£è³‡æ–™**: Liu 2024, Dual 2025, Hung 2021
- **XGBoost**: Liu 2024, Hung 2021, Dual 2025
- **Î´ç‰¹å¾µ / Î”ç‰¹å¾µ**: Dual 2025
- **é¡åˆ¥ä¸å¹³è¡¡ / SMOTE**: Liu 2024, Hung 2021

---

**æ–‡æª”å»ºç«‹æ—¥æœŸ**ï¼š2025-11-13
**æœ€å¾Œæ›´æ–°**ï¼š2026-01-09ï¼ˆæ–°å¢ Meeting 18-19 è«–æ–‡ï¼‰
**ç¶­è­·è€…**ï¼šç´€ä¼¯å–¬

---

## ğŸ”— å¿«é€Ÿå°èˆª

- ğŸ“‚ [è¿”å› Literature Notes ç›®éŒ„](.)
- ğŸ“Š [æŸ¥çœ‹ Q2 å°ç£æ–‡ç»å›é¡§](../research_plans/Q2_Taiwan_Literature_Review.md)
- ğŸ“‹ [æŸ¥çœ‹ç³»çµ±æ€§æ–‡ç»å›é¡§](Systematic_Literature_Review.md)
- ğŸ“– [Meeting 15-17 è«–æ–‡ç¸½çµ](Meeting_15-17_Papers_Summary.md)
- ğŸ¯ [Meeting 18 æœƒè­°ç´€éŒ„](../meeting_notes/Meeting_18_Notes.md)
- ğŸ“‘ [è«–æ–‡å€™é¸æ¸…å–®](../memos/è«–æ–‡å€™é¸æ¸…å–®_å¾Dual2025å»¶ä¼¸.md)
- ğŸ“ [Paper_SMOTE_SHAP_2025 ç­†è¨˜](../memos/Paper_SMOTE_SHAP_2025.md)
- ğŸ“ [Paper_Prediabetes_TaiwanMJ_2024 ç­†è¨˜](../memos/Paper_Prediabetes_TaiwanMJ_2024.md)
- ğŸ“ [Paper_China_Prediabetes_Diabetes_2025 ç­†è¨˜](summaries/Paper_China_Prediabetes_Diabetes_2025.md)
- ğŸ“ [Paper_Kanegae_Hypertension_2020 ç­†è¨˜](summaries/Paper_Kanegae_Hypertension_2020.md) â­ **Meeting 19 é¸å®š**
